Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.56 |
| ▸ | WNT3A | P56704 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24553788 | 1.00 | MAPK14 (0.56) | MAPK14CSNK1DWNT3AGSK3BMEN1 | |
| SCHEMBL24554160 | 0.92 | MAPK14 (0.50) | MAPK14CSNK1DWNT3AGSK3BNR3C2 | |
| SCHEMBL29683094 | 0.91 | NR3C2 (0.46) | MAPK14CSNK1DGSK3BNR3C2 | |
| SCHEMBL29683070 | 0.91 | MAPK14 (0.49) | MAPK14CSNK1DGSK3BNR3C2 | |
| SCHEMBL24554207 | 0.91 | NR3C2 (0.46) | MAPK14CSNK1DGSK3BNR3C2 | |
| SCHEMBL24554162 | 0.91 | MAPK14 (0.49) | MAPK14CSNK1DGSK3BNR3C2 | |
| SCHEMBL29683307 | 0.90 | MAPK14 (0.55) | MAPK14CSNK1DWNT3AGSK3B | |
| SCHEMBL24553851 | 0.90 | MAPK14 (0.55) | MAPK14CSNK1DWNT3AGSK3B | |
| SCHEMBL24554288 | 0.89 | RIPK3 (0.46) | MAPK14CSNK1DGSK3BNR3C2 | |
| SCHEMBL24553771 | 0.89 | MAPK14 (0.46) | MAPK14CSNK1DGSK3BNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276972-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| WO-2022127756-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276972-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | PACSIN2, CSNK1A1, CSNK1G3 | MAPK14 219/4885CSNK1D 12/4885WNT3A 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.